NCT03431142

Brief Summary

Current guidelines recommend that patients with ACS undergoing stent implantation might be offered extended DAPT treatment for up to 30 months if necessary. Therefore, we designed a prospective, multicenter, randomized, placebo-controlled trial among ACS patients with high-risk on ischemic and bleeding who received a new generation of DES and received 9 to 12 months of DAPT, and evaluated whether clopidogrel monotherapy reduce the risk of bleeding compared with clopidogrel plus ASA in the following 9 months and achieved non-inferior outcomes in preventing ischemic risk.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
7,758

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Feb 2018

Typical duration for phase_4

Geographic Reach
1 country

103 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 7, 2018

Completed
5 days until next milestone

Study Start

First participant enrolled

February 12, 2018

Completed
1 day until next milestone

First Posted

Study publicly available on registry

February 13, 2018

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2020

Completed
Last Updated

August 21, 2025

Status Verified

August 1, 2025

Enrollment Period

2.9 years

First QC Date

February 7, 2018

Last Update Submit

August 17, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Clinical relevant bleeding events

    defined as BARC type 2-5 bleeding events

    During 9-month follow up

Secondary Outcomes (2)

  • All bleeding events

    During 9-month follow up

  • Major adverse cardiovascular and cerebrovascular events(MACCE)

    During 9-month follow up

Study Arms (2)

Clopidogrel monotherapy

EXPERIMENTAL

On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue clopidogrel monotherapy in the following 9 months.

Drug: Clopidogrel

Clopidogrel plus aspirin

ACTIVE COMPARATOR

On the basis of 9-12 months of DAPT(aspirin+clopidogrel), continue DAPT (aspirin+clopidogrel) in the following 9 months.

Drug: Clopidogrel+aspirin

Interventions

Additional 9 months of clopidogrel monotherapy after 9-12 months of DAPT (aspirin+clopidogrel)

Clopidogrel monotherapy

Additional 9 months of clopidogrel plus aspirin after 9-12 months of DAPT (aspirin+clopidogrel)

Clopidogrel plus aspirin

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ACS patients undergoing PCI (New-Generation DES) and finishing 9-12 months of DAPT
  • \~ 85 years old adult patients
  • Patients under the age of 65 must meet at least one of the following clinical criteria of high bleeding risk and at least one of the following clinical criteria of high ischemic risk; Patients aged 65-75 must meet one of the following clinical criteria of either high bleeding risk or high ischemic risk.
  • Clinical criteria of high bleeding risk:
  • ≥75 years old
  • female
  • Iron deficiency anemia
  • history of stroke (hemorrhagic or ischemic)
  • ongoing medical treatment of diabetes (oral hypoglycemic agents or subcutaneous insulin)
  • Chronic kidney disease (eGFR \<60mL/min or creatinine clearance\<60mL/min)
  • Clinical criteria of high ischemic risk:
  • ≥75 years old
  • Multiple coronary lesions
  • target lesions required for stent of total length\> 30mm
  • Thrombotic target lesions
  • +8 more criteria

You may not qualify if:

  • Discontinuation or termination of DAPT treatment during the past 6 months due to adverse events (bleeding or ischemia) or other conditions
  • Surgery plan within 90 days
  • Coronary Revascularization (Surgical or Intervention) Program within 90 days
  • Dialysis-dependent renal failure
  • Moderate or severe hepatic insufficiency (2 times the upper limit of normal for ALT or AST)
  • Life expectancy \<1 year
  • Unable or unwilling to provide informed consent
  • Women with childbearing potential
  • Platelet count \<100000/mm3
  • Subjects undergoing warfarin or similar anticoagulant therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (103)

Anhui Provincial Hospital

Hefei, Anhui, 230001, China

Location

The Seventh Medical Center of Pla General Hospital

Beijing, Beijing Municipality, 100010, China

Location

Beijing Anzhen Hospital,Capital Medical University, word2

Beijing, Beijing Municipality, 100029, China

Location

Beijing Anzhen Hospital,Capital Medical University, word3

Beijing, Beijing Municipality, 100029, China

Location

PLA Rocket Force Characteristic Medical Center

Beijing, Beijing Municipality, 100088, China

Location

Peking University International Hospital

Beijing, Beijing Municipality, 102206, China

Location

Beijing Tsinghua Changgung Hospital

Beijing, Beijing Municipality, 102218, China

Location

Xinqiao Hospital Army Medical University

Chongqing, Chongqing Municipality, 400037, China

Location

Department of Cardiology, Daping Hospital, The Third Military Medical University

Chongqing, Chongqing Municipality, 400042, China

Location

University-Town Hospital Of Chongqing Medical University

Chongqing, Chongqing Municipality, 401331, China

Location

Fujian Medical University Union Hospital

Fuzhou, Fujian, 350001, China

Location

Fujian Provincial Hospital

Fuzhou, Fujian, 350001, China

Location

Guangdong General Hospital

Guangzhou, Guangdong, 510080, China

Location

The First Affiliated Hospital,Sun Yat-sen University

Guangzhou, Guangdong, 510080, China

Location

Guangzhou Red Cross Hospital

Guangzhou, Guangdong, 510235, China

Location

Meizhou People's Hospital

Meizhou, Guangdong, 514031, China

Location

Fuwai Hospital Chinese Academy Of Medical Sciences, Shenzhen

Shenzhen, Guangdong, 518057, China

Location

Zhongshan City People's Hospital

Zhongshan, Guangdong, 528403, China

Location

Liuzhou Worker's Hospital

Liuchow, Guangxi, 545007, China

Location

Cangzhou Central Hospital

Cangzhou, Hebei, 061011, China

Location

The First Hospital Of Hebei Medical University

Shijiazhuang, Hebei, 050000, China

Location

The Second Hospital Of Hebei Medical University

Shijiazhuang, Hebei, 050000, China

Location

Shijiazhuang People's Hospital

Shijiazhuang, Hebei, 050030, China

Location

Bethune International Peace Hospital

Shijiazhuang, Hebei, 050051, China

Location

Xinxiang Central Hospital

Xinxiang, Henan, 453099, China

Location

The First Affiliated Hospital Of Zhengzhou University

Zhengzhou, Henan, 450052, China

Location

Fuwai Central China Cardiovascular Hospital

Zhengzhou, Henan, 451460, China

Location

Wuhan Asia Heart Hospital

Wuhan, Hubei, 430022, China

Location

Wuhan Union Hospital China

Wuhan, Hubei, 430022, China

Location

Tongji Medical College Of Hust

Wuhan, Hubei, 430030, China

Location

People's Hospital Of Hunan Province

Changsha, Hunan, 410005, China

Location

The Third Xiangya Hospital Of Central South University

Changsha, Hunan, 410205, China

Location

Inner Mongolia People's Hospital

Hohhot, Inner Mongolia, 010017, China

Location

HulunBuir People's Hospital

Hulunbuir, Inner Mongolia, 021008, China

Location

Inner Mongolia Forestry General Hospital

Hulunbuir, Inner Mongolia, 022150, China

Location

Nanjing First Hospital

Nanjing, Jiangsu, 210006, China

Location

Nanjing Drum Tower Hospital

Nanjing, Jiangsu, 210008, China

Location

Zhongda Hospital Southeast University

Nanjing, Jiangsu, 210009, China

Location

Nanjing Jinling Hospital

Nanjing, Jiangsu, 210016, China

Location

Jiangsu Province Hospital

Nanjing, Jiangsu, 210029, China

Location

The First Affiliated Hospital Of Soochow University

Suzhou, Jiangsu, 215031, China

Location

Xuzhou Cancer Hospital

Xuzhou, Jiangsu, 221005, China

Location

The Second Affiliated Hospital Of Xuzhou Medical University

Xuzhou, Jiangsu, 221006, China

Location

The First Bethune Hospital Of Jilin University

Changchun, Jilin, 130021, China

Location

China-Japan Union Hospital Of Jilin University

Changchun, Jilin, 130033, China

Location

The Second Hospital Of Jilin University

Changchun, Jilin, 130041, China

Location

Jilin Central General Hospital

Jilin, Jilin, 132011, China

Location

Jilin City Hospital Of Chemical Industry, word1

Jilin, Jilin, 132021, China

Location

Jilin City Hospital Of Chemical Industry, word2

Jilin, Jilin, 132021, China

Location

Meihekou Central Hospital

Meihekou, Jilin, 135099, China

Location

Siping First People's Hospital

Siping, Jilin, 136001, China

Location

Anshan Center Hospital

Anshan, Liaoning, 114008, China

Location

Benxi Central Hospital

Benxi, Liaoning, 117099, China

Location

The First Affiliated Hospital Of Dalian Medical University

Dalian, Liaoning, 116011, China

Location

The Second Hospital Of Dalian Medical University

Dalian, Liaoning, 116023, China

Location

Dalian Friendship Hospital

Dalian, Liaoning, 116100, China

Location

Dandong Central Hospital

Dandong, Liaoning, 118002, China

Location

The First Affiliated Hospital Of Liaoning University Of Traditional Chinese Medicine

Shenyang, Liaoning, 110000, China

Location

The First Hospital Of China Medical University

Shenyang, Liaoning, 110002, China

Location

The Second Affiliated Hospital of Shenyang Medical College

Shenyang, Liaoning, 110002, China

Location

Shengjing Hospital Of China Medical University

Shenyang, Liaoning, 110004, China

Location

General Hospital of Northern Theater Command

Shenyang, Liaoning, 110016, China

Location

The Fourth Affiliated Hospital Of China Medical University

Shenyang, Liaoning, 110033, China

Location

The People's Hospital Of Liaoning Province

Shenyang, Liaoning, 110067, China

Location

Yingkou Central Hospital, word1

Yingkou, Liaoning, 115003, China

Location

Yingkou Central Hospital, word2

Yingkou, Liaoning, 115003, China

Location

The First Affiliated Hospital Of Baotou Medical College

Baotou, Neimonggol, 014017, China

Location

Baotou City Central Hospital

Baotou, Neimonggol, 014040, China

Location

Inner Mongolia People's Hospital

Hohhot, Neimonggol, 010017, China

Location

The First Affiliated Hospital Of Xi'an Jiaotong University

Xi'an, Shaanxi, 710061, China

Location

Shaanxi Provincial People's Hospital

Xi'an, Shaanxi, 710068, China

Location

Central Hospital Affiliated To Shandong First Medical University

Jinan, Shandong, 250013, China

Location

The General Hospital Of Jinan Military Command

Jinan, Shandong, 250031, China

Location

Qilu Hospital Of Shandong University

Jinan, Shandong, 250063, China

Location

Weihai Municipal Hospital

Weihai, Shandong, 264299, China

Location

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School Of Medicine

Shanghai, Shanghai Municipality, 200011, China

Location

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 200020, China

Location

Zhongshan Hospital

Shanghai, Shanghai Municipality, 200032, China

Location

Huashan Hospital,Fudan University

Shanghai, Shanghai Municipality, 200040, China

Location

Shanghai Tenth People's Hospital

Shanghai, Shanghai Municipality, 200072, China

Location

Shanghai Sixth People's Hospital Affiliated To Shanghai Jiaotong University

Shanghai, Shanghai Municipality, 200235, China

Location

Changhai Hospital

Shanghai, Shanghai Municipality, 200433, China

Location

Linfen Central Hospital

Linfen, Shanxi, 041099, China

Location

Shanxi Cardiovascular Hospital

Taiyuan, Shanxi, 030024, China

Location

Yuncheng Central Hospital

Yuncheng, Shanxi, 044099, China

Location

West China Hospital, Sichuan University

Chengdu, Sichuan, 610041, China

Location

Sichuan Provincial People's Hospital, word 1

Chengdu, Sichuan, 610072, China

Location

Sichuan Provincial People's Hospital, word 2

Chengdu, Sichuan, 610072, China

Location

The General Hospital Of Western Theater Command PLA

Chengdu, Sichuan, 610083, China

Location

General Hospital of Tianjin Medical University

Tianjin, Tianjin Municipality, 300052, China

Location

Tianjin Third Central Hospital

Tianjin, Tianjin Municipality, 300170, China

Location

Tianjin Chest Hospital, word1

Tianjin, Tianjin Municipality, 300222, China

Location

Tianjin Chest Hospital, word2

Tianjin, Tianjin Municipality, 300222, China

Location

The First Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, 830011, China

Location

The First Affiliated Hospital, Zhejiang University School Of Medicine

Hangzhou, Zhejiang, 310003, China

Location

Beijing Chao-Yang Hospital,Capital Medical University

Beijing, 100020, China

Location

Beijing Anzhen Hospital,Capital Medical University, word1

Beijing, 100029, China

Location

Fuwai Hospital Chinese Academy of Medical Sciences

Beijing, 100037, China

Location

Peking University People's Hospital

Beijing, 100044, China

Location

The Sixth Medical Center of PLA General Hospital

Beijing, 100048, China

Location

Beijing Hospital

Beijing, 100730, China

Location

Beijing Tongren Hospital,CMU

Beijing, 100730, China

Location

Beijing Luhe Hospital, Capital Medical University

Beijing, 101199, China

Location

Related Publications (2)

  • Li Y, Li J, Wang B, Jing Q, Zeng Y, Hou A, Wang Z, Liu A, Zhang J, Zhang Y, Zhang P, Jiang D, Liu B, Fan J, Zhang J, Li L, Su G, Yang M, Jiang W, Qu P, Zeng H, Li L, Qiu M, Ru L, Chen S, Zhou Y, Qiao S, Stone GW, Angiolillo DJ, Han Y; OPT-BIRISK Investigators. Extended Clopidogrel Monotherapy vs DAPT in Patients With Acute Coronary Syndromes at High Ischemic and Bleeding Risk: The OPT-BIRISK Randomized Clinical Trial. JAMA Cardiol. 2024 Jun 1;9(6):523-531. doi: 10.1001/jamacardio.2024.0534.

    PMID: 38630489BACKGROUND
  • Li Y, Jing Q, Wang B, Wang X, Li J, Qiao S, Chen S, Angiolillo DJ, Han Y. Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial. Am Heart J. 2020 Oct;228:1-7. doi: 10.1016/j.ahj.2020.07.005. Epub 2020 Jul 9.

    PMID: 32739652BACKGROUND

MeSH Terms

Conditions

Hemorrhage

Interventions

Clopidogrel

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

TiclopidineThienopyridinesThiophenesSulfur CompoundsOrganic ChemicalsPyridinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Yaling Han, MD

    The General Hospital of Northern Theater Command

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof.

Study Record Dates

First Submitted

February 7, 2018

First Posted

February 13, 2018

Study Start

February 12, 2018

Primary Completion

December 30, 2020

Study Completion

December 30, 2020

Last Updated

August 21, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations